Neurofilaments: a key new biomarker for clinicians. Part 1: Importance of neurofilaments in the management of neurodegenerative diseases

IF 0.4 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Annales de biologie clinique Pub Date : 2022-09-01 DOI:10.1684/abc.2022.1757

Constance Delaby, Olivier Bousiges, Damien Bouvier, Catherine Fillée, Anthony Fourier, Étienne Mondésert, Nicolas Nezry, Souheil Omar, Isabelle Quadrio, Benoit Rucheton, Susanna Schraen-Maschke, Vincent van Pesch, Stéphanie Vicca, Sylvain Lehmann, Aurélie Bedel

{"title":"Neurofilaments: a key new biomarker for clinicians. Part 1: Importance of neurofilaments in the management of neurodegenerative diseases","authors":"Constance Delaby, Olivier Bousiges, Damien Bouvier, Catherine Fillée, Anthony Fourier, Étienne Mondésert, Nicolas Nezry, Souheil Omar, Isabelle Quadrio, Benoit Rucheton, Susanna Schraen-Maschke, Vincent van Pesch, Stéphanie Vicca, Sylvain Lehmann, Aurélie Bedel","doi":"10.1684/abc.2022.1757","DOIUrl":null,"url":null,"abstract":"<p><p>Neurological biomarkers are of great use for clinicians, as they can be used for numerous purposes: guiding clinical diagnosis, estimating prognosis, assessing disease stage and monitoring progression or response to treatment. This field of neurology has evolved considerably in recent years due to analytical improvements in assay methods, now allowing the detection of biomarkers not only in cerebrospinal fluid (CSF) but also in blood. This progress greatly facilitates the repeated quantification of biomarkers, the collection of blood being much less invasive than that of CSF. Among the various informative biomarkers of neurological disorders, neurofilaments light chains (NfL) have proven to be particularly attractive in many contexts, in particular for the diagnosis and prognosis of neurodegenerative diseases (which this review will present), but also in other contexts of neurological disorders (which will be detailed in part 2). We further address the added value of NfL compared to other biomarkers commonly used to monitor the diseases described in this review.</p>","PeriodicalId":7892,"journal":{"name":"Annales de biologie clinique","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/abc.2022.1757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Neurological biomarkers are of great use for clinicians, as they can be used for numerous purposes: guiding clinical diagnosis, estimating prognosis, assessing disease stage and monitoring progression or response to treatment. This field of neurology has evolved considerably in recent years due to analytical improvements in assay methods, now allowing the detection of biomarkers not only in cerebrospinal fluid (CSF) but also in blood. This progress greatly facilitates the repeated quantification of biomarkers, the collection of blood being much less invasive than that of CSF. Among the various informative biomarkers of neurological disorders, neurofilaments light chains (NfL) have proven to be particularly attractive in many contexts, in particular for the diagnosis and prognosis of neurodegenerative diseases (which this review will present), but also in other contexts of neurological disorders (which will be detailed in part 2). We further address the added value of NfL compared to other biomarkers commonly used to monitor the diseases described in this review.

查看原文本刊更多论文

神经丝:临床医生重要的新生物标志物。第1部分:神经丝在神经退行性疾病治疗中的重要性

神经系统生物标志物对临床医生有很大的用处，因为它们可以用于许多目的:指导临床诊断，估计预后，评估疾病分期和监测进展或对治疗的反应。近年来，由于分析方法的改进，神经学的这一领域已经有了很大的发展，现在不仅可以检测脑脊液(CSF)中的生物标志物，还可以检测血液中的生物标志物。这一进展极大地促进了生物标志物的重复量化，血液的收集比脑脊液的收集侵入性小得多。在神经系统疾病的各种信息性生物标志物中，神经丝轻链(NfL)已被证明在许多情况下特别有吸引力，特别是在神经退行性疾病的诊断和预后方面(本文将介绍)，但也在其他神经系统疾病的情况下(将在第2部分详细介绍)。我们进一步讨论了NfL与其他生物标志物相比的附加价值，这些生物标志物通常用于监测本综述中描述的疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales de biologie clinique 医学-医学：研究与实验

CiteScore

0.80

自引率

20.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Multidisciplinary information with direct relevance to everyday practice Annales de Biologie Clinique, the official journal of the French Society of Clinical Biology (SFBC), supports biologists in areas including continuing education, laboratory accreditation and technique validation. With original articles, abstracts and accounts of everyday practice, the journal provides details of advances in knowledge, techniques and equipment, as well as a forum for discussion open to the entire community.